Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Jack Clark, Anthropic’s co-founder, left on paternity leave last November. When he returned in February, he was surprised to ...

Koray Kavukcuoglu, DeepMind's chief technology officer and Google's chief AI architect, is taking on the operational ...

Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while ...

Management lowered 2026 full-year cash operating expense guidance to $375 million, representing a nearly 40% reduction from 2024 pro forma expenses through improved ROI on technology. Additional Phase ...

Key Points Interested in Recursion Pharmaceuticals, Inc.? Here are five stocks we like better. Recursion advanced its ...

You might think you're done with the multiverse, but the multiverse is not done with you, as Apple TV preps the next season ...

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago. These ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $131 ...

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar ...